29969-15-1

Basic information

• Product Name: 2-(3-Trifluoromethyl-phenoxy)-ethylamine
• Synonyms: 2-(3-Trifluoromethyl-phenoxy)-ethylamine
• CAS NO: 29969-15-1
• Molecular Formula: C₉H₁₀F₃NO
• Molecular Weight: 205.1770096
• Mol File: 29969-15-1.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 243°Cat760mmHg
• Flash Point: 100.8°C
• Appearance: /
• Density: 1.227g/cm³
• Vapor Pressure: 0.0329mmHg at 25°C
• Refractive Index: 1.463
• PKA: 8.40±0.10(Predicted)
• CAS DataBase Reference: 2-(3-Trifluoromethyl-phenoxy)-ethylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-Trifluoromethyl-phenoxy)-ethylamine(29969-15-1)
• EPA Substance Registry System: 2-(3-Trifluoromethyl-phenoxy)-ethylamine(29969-15-1)

Safety Data

• Hazardous Substances Data: 29969-15-1(Hazardous Substances Data)

Usage

Chemical class

Amine

Functional groups

Trifluoromethyl group attached to a phenoxy ring

Usage

Intermediate in the synthesis of pharmaceuticals, agrochemicals, and specialty chemicals

Potential applications

Medicine and biological research

Safety

Handle with care and follow safety protocols to prevent potential hazards.

InChI:InChI=1/C9H10F3NO/c10-9(11,12)7-2-1-3-8(6-7)14-5-4-13/h1-3,6H,4-5,13H2

Upstream product

• 321432-39-7 2-(2-(3-(trifluoromethyl)phenoxy)ethyl)isoindoline-1,3-dione 
• 18800-39-0 1-bromo-2-(3-trifluoro-methyl-phenoxy)-ethane 
• 98-17-9 3-Trifluoromethylphenol 

Downstream Products

• 113295-67-3 2-Isopropyl-5-[2-(3-trifluoromethyl-phenoxy)-ethylamino]-2-(3,4,5-trimethoxy-phenyl)-pentanenitrile 

Relevant articles and documents

Discovery of Novel pERK1/2- or β-Arrestin-Preferring 5-HT1AReceptor-Biased Agonists: Diversified Therapeutic-like versus Side Effect Profile

Novel 1-(1-benzoylpiperidin-4-yl)methanamine derivatives with high affinity and selectivity for serotonin 5-HT1A receptors were obtained and tested in four functional assays: ERK1/2 phosphorylation, adenylyl cyclase inhibition, calcium mobilization, and β-arrestin recruitment. Compounds 44 and 56 (2-methylaminophenoxyethyl and 2-(1H-indol-4-yloxy)ethyl derivatives, respectively) were selected as biased agonists with highly differential "signaling fingerprints"that translated into distinct in vivo profiles. In vitro, 44 showed biased agonism for ERK1/2 phosphorylation and, in vivo, it preferentially exerted an antidepressant-like effect in the Porsolt forced swimming test in rats. In contrast, compound 56 exhibited a first-in-class profile: it preferentially and potently activated β-arrestin recruitment in vitro and potently elicited lower lip retraction in vivo, a component of "serotonergic syndrome". Both compounds showed promising developability properties. The presented 5-HT1A receptor-biased agonists, preferentially targeting various signaling pathways, have the potential to become drug candidates for distinct central nervous system pathologies and possessing accentuated therapeutic activity and reduced side effects.

SUBSTITUTED 2H-[1,2,4]TRIAZOLO[4,3-A]PYRAZINES AS GSK-3 INHIBITORS

The invention relates to compounds of formula (I) prodrugs thereof, and the pahrmaceutically acceptabel salts of the compounds and prodrugs, wherein Ra, Rb, R1 and R2 are as defined herein; pharmaceutical compositions thereof; and uses thereof.